Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis

Journal of the American Academy of Dermatology

Volumn 49, Issue 2, 2003, Pages 316-319

  Huang, Yau Li ^a   Hong, Hong Shang ^a   Wang, Zen Whe ^a   Kuo, Tseng tong ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PROPRANOLOL; VALPROIC ACID; VANCOMYCIN;

ARTICLE; BACTERIAL PNEUMONIA; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DROWSINESS; DRUG FATALITY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; FEVER; HAND FOOT AND MOUTH DISEASE; HEPATOMEGALY; HUMAN; HYPERSENSITIVITY REACTION; JAUNDICE; LICHENOID ERUPTION; LIVER TOXICITY; LYMPHADENOPATHY; MYOCLONUS SEIZURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RASH; SKIN BIOPSY; TOXIC HEPATITIS; TREATMENT OUTCOME;

EID: 0042133150     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0190-9622(03)00748-5     Document Type: Article

References (12)

1. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988;82:1826-32.
2. Colletti RB, Trainer TD, Krawisz BR. Reversible valproate fulminant hepatic failure. J Pediatr Gastroenterol Nutr 1986;5:990-4.
3. Tennis P, Stern RS. Risk of serious cutaneous disorder after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-6.
4. Picart N, Periole B, Mazereeuw J, Bonafe JL. Drug hypersensitivity syndrome to valproic acid. Presse Med 2000;29:648-50.
5. Plantin P, Cartier H, Le Bihan G, Cclouard P, Lellouche F, Leroy JP. Drug hypersensitivity syndrome during treatment with valproic acid. Presse Med 1995;24:1624.
6. Sullivan JR, Shear NH. The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001;137:357-64.
7. Descamps V, Bouscarat F, Laglenne S, Aslangul E, Veber B, Descamps D, et al. Human herpes virus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome. Br J Dermatol 1997;137:605-8.
8. Mizukawa Y, Shiohara T. Virus-induced immune dysregulation as a triggering factor for the development of drug rashes and autoimmune diseases: with emphasis on EB virus, human herpes virus 6 and hepatitis C virus. J Dermatol Sci 2000;22:169-80.
9. Knowles S, Shapiro L, Shear N. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21:489-501.
10. Frenichel GM, Greene HL. Valproate hepatotoxicity: two new cases, a summary of others, and recommendations. Pediatr Neurol 1985;1:109-13.
11. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982;2:591-7.
12. Jeavons PM. Non-dose-related side effects of valproate. Epilepsia 1984;25(Suppl):S50-5.